Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opioid-sparing care pathway for obesity surgery
2023-505934-86-00Phase 4Authorised
- Sponsor
- Region Västra Götaland
- Start
- Mar 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of esketamine, remifentanil, dexmedetomidine and lidocaine in postoperative pain (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Postoperative pain score equivalence/non-inferiority on Numeric Rating Scale. Planned start Mar 2019; status: authorised.
02
Drugs
esketamineremifentanildexmedetomidinelidocaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on 2023-505934-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505934-86-00.